Results 21 to 30 of about 11,189 (206)

THE EFFECT OF BROMOCRIPTINE ON C-REACTIVE PROTEIN IN WOMEN WITH HYPERPROLACTINEMIC AMENORRHEA [PDF]

The Medical Journal of Basrah University, 2008
C-reactive protein has become the subject of avid interest in recent years. Increased concentrations of C-reactive protein (CRP) became widely accepted as a risk factor of many inflammatory diseases including atherosclerosis, ischemic vascular diseases ...
Isam Hamo Mahmood
doaj   +1 more source

Protective Role of Sarpogrelate in Combination with Bromocriptine and Cabergoline for Treatment of Diabetes in Alloxan-induced Diabetic Rats

Current Therapeutic Research, 2021
: Background: Although dopamine D2 receptor agonists, bromocriptine and cabergoline, are notable medications in the treatment of Parkinsonism, hyperprolactinemia, and hyperglycemia, there is an identified relationship between the utilization of D2-like ...
Mohammed Fouad Shalaby, MD, Hekma A. Abd El Latif, PhD, Mohamed El Yamani, PhD, May Ahmed Galal, PhD, Sherifa Kamal, PhD, Ikhlas Sindi, PhD   +5 more
doaj   +1 more source

Cardiac valvular abnormalities associated with use and cumulative exposure of cabergoline for hyperprolactinemia: the CATCH study

BMC Endocrine Disorders, 2020
Background Whether lower dose cabergoline therapy for hyperprolactinemia increases risk of valvular dysfunction remains controversial. We examined valvular abnormalities among asymptomatic adults with hyperprolactinemia treated with dopamine agonists ...
Amer Budayr, Thida C. Tan, Joan C. Lo, Jonathan G. Zaroff, Grace H. Tabada, Jingrong Yang, Alan S. Go   +6 more
doaj   +1 more source

Rapid and dramatic glucose‐lowering effect of bromocriptine in an inadequately controlled type 2 diabetes patient with prolactinoma

Journal of Diabetes Investigation, 2021
Dopamine receptor agonists are typically used to treat Parkinson’s disease and certain pituitary tumors, such as prolactinoma or a growth hormone‐producing tumor.
Motoyuki Igata, Yoshitaka Yagi, Satoko Hanatani, Masaji Sakaguchi, Norio Ishii, Kayo Yoshinaga, Junji Kawashima, Hiroyuki Motoshima, Eiichi Araki   +8 more
doaj   +1 more source

Effect of bromocriptine on glycemic control, risk of cardiovascular diseases and weight in patients with type 2 diabetes: a systematic review

Diabetology & Metabolic Syndrome, 2023
Background Type 2 diabetes (T2DM) patients, including those in good glycemic control, have an increased risk of cardiovascular disease (CVD). Maintaining good glycemic control with drugs may reduce long-term CVD risk.
Mulualem Tesfaye Birhan, Teklie Mengie Ayele, Fikire Wondimu Abebe, Fiseha Nigussie Dgnew   +3 more
doaj   +1 more source

Depot-bromocriptine treatment for prolactinomas and acromegaly. [PDF]

, 1986
Fifteen patients with hyperprolactinaemia and pituitary macroadenomas (5 patients), microadenomas (6 patients), or acromegaly (4 patients) were given a single intramuscular injection of 50 mg bromocriptine bound to polylactic acid microspheres, depot ...
Grossman, Ashley, A. GROSSMAN, Ross, R, R. ROSS, G. M. BESSER, J. A. H. WASS, Wass, JA, Grossman, A, Besser, GM   +8 more
core   +1 more source

Effects of Bromocriptine on Glucose and Insulin Dynamics in Normal and Insulin Dysregulated Horses

Frontiers in Veterinary Science, 2022
The objectives of the study were to study the effects of the synthetic ergot alkaloid (EA), bromocriptine, on glucose and lipid metabolism in insulin dysregulated (ID, n = 7) and non-ID (n = 8) mares. Horses were individually housed and fed timothy grass
Caroline M. M. Loos, Kristine L. Urschel, Eric S. Vanzant, Erin L. Oberhaus, Adam D. Bohannan, James L. Klotz, Kyle R. McLeod   +6 more
doaj   +1 more source

Table_1_Repurposing of Bromocriptine for Cancer Therapy.docx [PDF]

, 2018
Bromocriptine is an ergot alkaloid and dopamine D2 receptor agonist used to treat Parkinson’s disease, acromegaly, hyperprolactinemia, and galactorrhea, and more recently diabetes mellitus.
Yoshikazu Sugimoto (151140), Henry Johannes Greten (5828054), Ean-Jeong Seo (3695242), Thomas Efferth (33075)   +3 more
core   +1 more source

Circadian‐timed quick‐release bromocriptine lowers elevated resting heart rate in patients with type 2 diabetes mellitus

Endocrinology, Diabetes & Metabolism, 2020
Objective Sympathetic nervous system (SNS) overactivity is a risk factor for insulin resistance and cardiovascular disease (CVD). We evaluated the impact of bromocriptine‐QR, a dopamine‐agonist antidiabetes medication, on elevated resting heart rate (RHR)
Bindu Chamarthi, Aaron Vinik, Michael Ezrokhi, Anthony H. Cincotta   +3 more
doaj   +1 more source

Therapeutic activity of sarpogrelate and dopamine D2 receptor agonists on cardiovascular and renal systems in rats with alloxan-induced diabetes

BMC Pharmacology and Toxicology, 2021
Background Dopamine D2 receptor agonists, bromocriptine and cabergoline, are notable medications in the treatment of Parkinsonism, hyperprolactinemia, and hyperglycemia.
Mohammed Ahmed Fouad Shalaby, Hekma A. Abd El Latif, Mohamed El Yamani, May Ahmed Galal, Sherifa Kamal, Ikhlas Sindi, Raneem Masaood   +6 more
doaj   +1 more source